highperformr logo

AffaMed Therapeutics's Overview

Total employees40
HeadquartersShanghai
Founded2019

AffaMed Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing transformative pharmaceutical products to address significant unmet medical needs in ophthalmic, neurological, and psychiatric disorders. Co-founded and incubated by CBC Group, AffaMed leverages its robust R&D capabilities and strategic partnerships to advance a diverse pipeline of therapies, with a primary focus on patients in Greater China and a vision for global impact. Their approach emphasizes scientific innovation, clinical excellence, and a patient-first mindset.

Where is AffaMed Therapeutics's Headquarters?

AffaMed Therapeutics officeAffaMed Therapeutics officeAffaMed Therapeutics officeAffaMed Therapeutics office
*Images sourced via web search. Rights belong to original owners

HQ Function

The Shanghai headquarters serves as the core for strategic leadership, research and development program management, business development for the Greater China region, and overall corporate operations.

Notable Features:

Situated in a modern biopharmaceutical park in Pudong, the headquarters benefits from state-of-the-art facilities and proximity to a rich ecosystem of research institutions, talent, and potential collaborators.

Work Culture:

AffaMed cultivates a work environment that is innovative, collaborative, and results-driven. There's a strong emphasis on scientific rigor, ethical conduct, and a shared passion for making a difference in patients' lives.

HQ Significance:

The Shanghai headquarters is crucial for AffaMed's mission, anchoring its operations in one of the world's fastest-growing healthcare markets and serving as a bridge for global drug development efforts.

Values Reflected in HQ: The headquarters' location and focus mirror AffaMed's core values of innovation, patient-centricity, global collaboration, and excellence in execution within the biopharmaceutical landscape.

Location:

AffaMed Therapeutics maintains a strategic global presence with offices in Shanghai (China), Boston (USA), Hong Kong SAR, and Seoul (South Korea). This international footprint supports comprehensive global functions including R&D, clinical trial management across multiple regions, regulatory interactions with key health authorities (e.g., NMPA, FDA, MFDS), global business development, and strategic alliance management to advance its therapeutic pipeline in ophthalmology and CNS disorders worldwide.

Street Address:

Building 7, Lane 88, Shengrong Road, Pudong

City:

Shanghai

State/Province:

Shanghai

Country:

China

AffaMed Therapeutics's Global Presence

Boston, MA, USA

Address: 800 Boylston Street, 16th Floor, Boston, MA 02199, USA

Facilitates collaboration with US-based research institutions, partners, and regulatory authorities like the FDA. Supports global clinical trial operations and talent acquisition in North America.

Hong Kong SAR, China

Address: Unit 702, 7/F, Lee Garden Two, 28 Yun Ping Road, Causeway Bay, Hong Kong

Supports AffaMed's corporate finance, legal, and business development activities in Asia, capitalizing on Hong Kong's status as a global financial center.

Seoul, South Korea

Address: 14F, Tower 8, 7 Jong-ro 5-gil, Jongno-gu, Seoul, Republic of Korea 03157

Drives AffaMed's clinical trial execution, regulatory submissions, and commercial preparation in South Korea, a significant market for innovative biopharmaceuticals in Asia.

Buying Intent Signals for AffaMed Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of AffaMed Therapeutics

As of April 2025, AffaMed Therapeutics' leadership includes:

Dr. Dayao Zhao - Chief Executive Officer
Dr. Ji Li - President and Chief Medical Officer
Dr. Eddy Wu - Chief Operating Officer
David R. Weber - Chief Financial Officer
Dr. Vijay Sabesan - Chief Business Officer
Dr. Borwen Huang - Chief Technology Officer

Investors of AffaMed Therapeutics

AffaMed Therapeutics has been backed by several prominent investors over the years, including:

CBC Group (formerly C-Bridge Capital)
Lake Bleu Capital
Matrix Partners China
Vertex Ventures China
Oriza Holdings
Vivo Capital
TF Capital
Legend Capital

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits0

In the past 12-18 months, AffaMed Therapeutics notably strengthened its executive team with the appointment of Dr. Eddy Wu as Chief Operating Officer. No major C-suite departures have been publicly announced during this period.

New Appointments:

Dr. Eddy Wu, Dr. Eddy Wu joined AffaMed Therapeutics as Chief Operating Officer, tasked with optimizing operational efficiency and supporting the company's growth.

Technology (Tech Stack) used by AffaMed Therapeutics

Discover the tools AffaMed Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

AffaMed Therapeutics Email Formats and Examples

While AffaMed Therapeutics's exact primary email format isn't publicly disclosed, companies of its nature commonly use patterns like first initial followed by last name, or first name separated from the last name by a period, at their domain affamed.com.

[first_initial][last_name]@affamed.com or [first_name].[last_name]@affamed.com

Format

jdoe@affamed.com or jane.doe@affamed.com

Example

75%

Success rate

News and media

AffaMed Therapeutics WebsiteMarch 26, 2024

AffaMed Therapeutics Doses First Patient in Phase III Trial of DEXTENZA® for Allergic Conjunctivitis in China

AffaMed Therapeutics announced the dosing of the first patient in its China Phase III clinical trial (AM011-CN003) of DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for the treatment of ocular itching associated with allergic conjunctivitis. This is a key milestone for bringing DEXTENZA® to patients in China....more

AffaMed Therapeutics WebsiteJanuary 16, 2024

AffaMed Therapeutics and Kissei Pharmaceutical Announce First Patient Dosed in Phase I Clinical Trial of KDT-3594 for Amyotrophic Lateral Sclerosis (ALS) in China

AffaMed Therapeutics, in collaboration with Kissei Pharmaceutical Co., Ltd., announced the dosing of the first patient in a Phase I clinical trial of KDT-3594 in China. KDT-3594 is being investigated as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)....more

AffaMed Therapeutics WebsiteJune 27, 2023

AffaMed Therapeutics Appoints Seasoned Industry Leader Dr. Eddy Wu as Chief Operating Officer

AffaMed Therapeutics announced the appointment of Dr. Eddy Wu as its Chief Operating Officer. Dr. Wu brings over two decades of experience in the biopharmaceutical industry, including operations, quality, manufacturing, and supply chain management....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including AffaMed Therapeutics, are just a search away.